ATE304856T1 - Methode zur verabreichung von biphosphonaten - Google Patents

Methode zur verabreichung von biphosphonaten

Info

Publication number
ATE304856T1
ATE304856T1 AT01940580T AT01940580T ATE304856T1 AT E304856 T1 ATE304856 T1 AT E304856T1 AT 01940580 T AT01940580 T AT 01940580T AT 01940580 T AT01940580 T AT 01940580T AT E304856 T1 ATE304856 T1 AT E304856T1
Authority
AT
Austria
Prior art keywords
bisphosphonates
administration
biphosphonates
osteoporosis
potent
Prior art date
Application number
AT01940580T
Other languages
English (en)
Inventor
Zebulun D Horowitz
Peter C Richardson
Ulrich Trechsel
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE304856(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE304856T1 publication Critical patent/ATE304856T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01940580T 2000-06-20 2001-06-18 Methode zur verabreichung von biphosphonaten ATE304856T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59713500A 2000-06-20 2000-06-20
US26768901P 2001-02-09 2001-02-09
PCT/EP2001/006850 WO2001097788A2 (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates

Publications (1)

Publication Number Publication Date
ATE304856T1 true ATE304856T1 (de) 2005-10-15

Family

ID=26952565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01940580T ATE304856T1 (de) 2000-06-20 2001-06-18 Methode zur verabreichung von biphosphonaten

Country Status (24)

Country Link
US (1) US8052987B2 (de)
EP (1) EP1296689B3 (de)
JP (2) JP4722375B2 (de)
KR (1) KR100864743B1 (de)
CN (1) CN1272013C (de)
AT (1) ATE304856T1 (de)
AU (2) AU2001274109B2 (de)
BR (1) BR0111806A (de)
CA (1) CA2410201C (de)
CY (2) CY1113740T1 (de)
CZ (1) CZ301972B6 (de)
DE (1) DE60113537T3 (de)
DK (1) DK1296689T3 (de)
ES (2) ES2247123T7 (de)
HU (1) HU228400B1 (de)
IL (2) IL153229A0 (de)
MX (1) MXPA02012682A (de)
NO (1) NO330459B1 (de)
NZ (1) NZ523086A (de)
PL (1) PL203087B1 (de)
PT (1) PT1591122E (de)
SK (1) SK287278B6 (de)
TW (1) TWI289451B (de)
WO (1) WO2001097788A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
MXPA02012682A (es) 2000-06-20 2003-04-25 Novartis Ag Metodo para administrar bisfosfonatos.
EP1192945A3 (de) * 2000-09-21 2004-03-03 Pfizer Products Inc. Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung von Osteoarthritis
JP2004526747A (ja) * 2001-04-03 2004-09-02 ザ ロイヤル アレクサンドラ ホスピタル フォー チルドレン 骨移植で使用される医薬
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
KR20150053811A (ko) * 2002-05-10 2015-05-18 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
JP2006500402A (ja) * 2002-09-16 2006-01-05 ノバルティス　アクチエンゲゼルシャフト 股関節骨折後における二次骨折の予防または低減化方法
TW200410701A (en) * 2002-10-15 2004-07-01 Novartis Ag Method of administering bisphosphonates
RU2315603C2 (ru) 2002-12-20 2008-01-27 Ф.Хоффманн-Ля Рош Аг Композиция с высокой дозой ибандроната
EP1709968A1 (de) * 2004-01-30 2006-10-11 Astellas Pharma Inc. P2x rezeptor-hemmer
ATE495747T1 (de) * 2004-08-23 2011-02-15 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
WO2006062876A2 (en) * 2004-12-09 2006-06-15 Merck & Co., Inc. Estrogen receptor modulators
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
CN105232482A (zh) * 2006-04-07 2016-01-13 默里昂研究Iii有限公司 包含增强剂的固体口服剂型
US20090075941A1 (en) * 2006-04-21 2009-03-19 The Uab Research Foundation Treating neoplasms
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
AU2009244799B2 (en) * 2008-05-07 2014-11-20 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011014766A2 (en) 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2473172B1 (de) 2009-09-01 2015-04-08 Duke University Bisphosphonatzusammensetzungen und verfahren zur behandlung von herzfehlern
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN104010647A (zh) 2011-11-16 2014-08-27 杜克大学 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法
CN103623465B (zh) * 2013-11-21 2015-12-30 彭江 一种可局部调节成破骨活性的组织工程骨支架及制备方法
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
KR20180115979A (ko) * 2017-04-14 2018-10-24 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
JP2022536222A (ja) * 2018-11-02 2022-08-15 アンパサンド バイオファーマシューティカルズ インコーポレイテッド 局所的に施用される緩衝液によるカチオン過負荷および電解質平衡異常のリスクの管理
KR102049233B1 (ko) * 2019-01-14 2019-11-28 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594329A (en) * 1897-11-23 Socket or collet
DE3232959A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE114473T1 (de) 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4812304A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
ATE72816T1 (de) 1986-11-21 1992-03-15 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
CA2124792C (en) 1991-12-17 2000-07-04 Ann D. Geddes Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
DK0648120T3 (da) 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (de) 1992-11-30 1994-06-08 Ciba-Geigy Ag Verwendung von Methanbiphosphonsäurederivaten zur Herstellung eines Arzneimittels zur Behandlung von Knochenbrüchen
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
GB9408775D0 (en) 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
KR970705399A (ko) 1994-09-09 1997-10-09 레이셔 야코버스 코넬리스 골다공증용 포스포네이트 및 부갑상성 호르몬(phosphonates and parathyroid hormone for osteoporosis)
WO1996007417A1 (en) 1994-09-09 1996-03-14 The Procter & Gamble Company Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
US6057306A (en) 1995-09-29 2000-05-02 Novartis Corporation Method of treating the navicular disease in horses
US5735810A (en) 1996-06-14 1998-04-07 Becton Dickinson And Company Device for the iontophoretic administration of bisphosphonates
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
AU8493698A (en) 1997-07-22 1999-02-16 Merck & Co., Inc. Method for inhibiting bone resorption
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
SE9703691D0 (sv) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
CN1202828C (zh) * 1999-05-21 2005-05-25 诺瓦提斯公司 二膦酸在制备抑制或逆转血管发生的药物中的用途
US20010044427A1 (en) 1999-12-20 2001-11-22 Sidney Mazel Pharmaceutical kit
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
MXPA02012682A (es) 2000-06-20 2003-04-25 Novartis Ag Metodo para administrar bisfosfonatos.

Also Published As

Publication number Publication date
CN1272013C (zh) 2006-08-30
US20030181421A1 (en) 2003-09-25
PL203087B1 (pl) 2009-08-31
NO20026117L (no) 2002-12-19
HK1072539A1 (en) 2005-09-02
DE60113537D1 (de) 2006-02-02
EP1296689B1 (de) 2005-09-21
SK18082002A3 (sk) 2003-08-05
BR0111806A (pt) 2003-05-20
AU7410901A (en) 2002-01-02
EP1296689B3 (de) 2013-02-13
TWI289451B (en) 2007-11-11
CZ301972B6 (cs) 2010-08-18
NO330459B1 (no) 2011-04-18
EP1296689A2 (de) 2003-04-02
CY2013011I2 (el) 2015-08-05
CA2410201C (en) 2010-10-26
JP2005247873A (ja) 2005-09-15
AU2001274109B2 (en) 2004-12-23
NO20026117D0 (no) 2002-12-19
JP5005188B2 (ja) 2012-08-22
NZ523086A (en) 2007-07-27
CZ20024134A3 (cs) 2003-06-18
HUP0301164A2 (hu) 2003-08-28
PL358224A1 (en) 2004-08-09
MXPA02012682A (es) 2003-04-25
DE60113537T3 (de) 2013-05-29
SK287278B6 (sk) 2010-05-07
KR100864743B1 (ko) 2008-10-22
CA2410201A1 (en) 2001-12-27
HU228400B1 (en) 2013-03-28
IL153229A0 (en) 2003-07-06
ES2394211T3 (es) 2013-01-23
ES2247123T7 (es) 2013-03-01
DK1296689T3 (da) 2005-11-28
DE60113537T2 (de) 2006-06-29
PT1591122E (pt) 2012-12-12
JP2003535889A (ja) 2003-12-02
HUP0301164A3 (en) 2005-11-28
JP4722375B2 (ja) 2011-07-13
ES2247123T3 (es) 2006-03-01
CY1113740T1 (el) 2015-08-05
WO2001097788A2 (en) 2001-12-27
IL153229A (en) 2007-07-24
WO2001097788A3 (en) 2002-06-27
CN1620300A (zh) 2005-05-25
CY2013011I1 (el) 2015-08-05
US8052987B2 (en) 2011-11-08
KR20030015283A (ko) 2003-02-20

Similar Documents

Publication Publication Date Title
DE60113537D1 (de) Methode zur verabreichung von biphosphonaten
DE69905488D1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
DE60129242D1 (de) Verwendung von zoledronsäure zur schmerzbehandlung
SE9901272D0 (sv) New improved formulation
MY140080A (en) Treatment and prevention of osteoporosis
PL1656386T3 (pl) Proces wytwarzania związków kwasu difosfonowego
DK0756484T3 (da) Vådgranuleringsformulering til diphosphonsyrer
ATE471149T1 (de) Verwendung von bisphosphonaten zur behandlung von vaskulärer restenose
ATE293450T1 (de) Verwendung von biphosphonsäuren zur behandlung von angiogenese
ATE357921T1 (de) Alendronate zur behandlung von osteoporose
NO20032706L (no) Fosfatstabiliserende sammensetninger
ATE253368T1 (de) Verwendung von bisphosphonaten zur prophylaxe und zur behandlung von infektiösen prozessen
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
DK0994884T3 (da) Diphosphonsyresalte til behandling af osteoporose
DE60212621D1 (de) Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis
DE69916326D1 (de) Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
DK1089761T3 (da) Lægemidler indeholdende bisphosphonsyrer og derivater deraf til profylakse og behandling af autoimmunsygdomme samt af allergier
PT1803727E (pt) Processo melhorado para o fabrico de ácido 4-amino-hidroxibutilideno-1,1 bisfosfónico e seus sais

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1296689

Country of ref document: EP